Jianxiang Shi

Also affiliated with Henan Cancer Hospital

MedicineImmunology and MicrobiologyBiochemistry, Genetics and Molecular Biology

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

1in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Why this DataRank?

An author's DataRank is the sum of the DataRanks of all 1 indexed paper attributed to them. A prolific author with many moderate-impact papers can outrank one with a single high-impact paper.

Author scores recompute whenever paper DataRanks are refreshed, so this number lags the underlying paper scores by at most one batch run.

Read the full methodology →

Papers

Driven by 2 papers. Top paper: “Feasibility and tolerability of sintilimab plus anlotinib as the second‐line therapy for patients with advanced biliary tract cancers: An open‐label, single‐arm, phase II clinical trial”.

Feasibility and tolerability of sintilimab plus anlotinib as the second‐line therapy for patients with advanced biliary tract cancers: An open‐label, single‐arm, phase II clinical trial

International Journal of Cancer(2023)10.1002/ijc.34372

N/A

0.529DataRank · unranked

33 citations

Ruihua Zhao, Chuang Zhou, Qian Zhong, Jianxiang Shi, Chang Su +21 more

Using protein microarray to identify and evaluate autoantibodies to tumor‐associated antigens in ovarian cancer

Cancer Science(2020)10.1111/cas.14732

N/A

0DataRank · unranked

58 citations

Xiao Wang, Cuipeng Qiu, Jiejie Qin, Keyan Wang, Guiying Sun +10 more